Last reviewed · How we verify
NCT06817161: ESTANVO
Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer:
Phase 3 trial testing transcutaneous auricular vagus nerve stimulation in Ovarian Carcinoma in 116 participants. Currently enrolling.
30 June 2028
Quick facts
| Lead sponsor | Centre Francois Baclesse |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | other |
| Enrollment | 116 |
| Start date | 30 April 2025 |
| Primary completion | 30 June 2028 |
| Estimated completion | 30 September 2028 |
| Sites | 4 locations across France |
Drugs / interventions tested
- transcutaneous auricular vagus nerve stimulation
- Placebo device
Conditions studied
- Ovarian Carcinoma — all drugs for Ovarian Carcinoma →
- First Line Chemotherapy — all drugs for First Line Chemotherapy →
- Digestive System Disorders — all drugs for Digestive System Disorders →
Sponsor
Centre Francois Baclesse — full company profile →
Who can join
18 and older, female only, with Ovarian Carcinoma or First Line Chemotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Impact of stimulation of parasympathetic activity by transcutaneous auricular vagus nerve stimulation (taVNS) on quality of life (QoL) relating to digestive symptoms in patients undergoing first-line treatment for ovarian cancer, as compared to shame taVNS
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06817161
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of transcutaneous auricular vagus nerve stimulation
Trials testing the same drug.
- NCT07192757 — Improving Speech in Noise Perception for Individuals With Age-related Hearing Loss · NA · recruiting
- NCT07344402 — Optimization of taVNS Intervention Strategies for Refractory Constipation · NA · recruiting
- NCT06822140 — Effect of Vagus Nerve Stimulation Via the Outer Ear on Motor and Cognitive Deficits After Ischemic Stroke · NA · not yet recruiting
- NCT07022171 — Mechanisms of Transcutaneous Auricular Vagus Nerve Stimulation in Depression · NA · recruiting
- NCT06975124 — taVNS Effects on Fear Ratings in Naturalistic Context · Phase 1 · recruiting
Other recruiting trials for Ovarian Carcinoma
Currently open trials in the same condition.
- NCT07282158 — Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians · NA · recruiting
- NCT07280312 — Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions · NA · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT06964009 — DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer · Phase 1 · recruiting
- NCT07118176 — Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers · Phase 1 · recruiting
Other Centre Francois Baclesse trials
Trials by the same sponsor.
- NCT06959810 — Impact of Adapted Aesthetic Onco in Patients With Upper Aerodigestive Tract Cancer During Their Management · NA · recruiting
- NCT06792721 — MEASUREMENT OF CIRCULATING MUTATION BURDEN · recruiting
- NCT06612827 — Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions · recruiting
- NCT06798922 — Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers · Phase 3 · recruiting
- NCT06603506 — Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06817161 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Francois Baclesse
- Last refreshed: 7 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06817161.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing